Abstract Number: 0605 • ACR Convergence 2024
Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
Background/Purpose: IL-23 is implicated in the pathogenesis of psoriasis (PsO), and myeloid cells that express FcγRI (CD64) have been identified as a primary source of…Abstract Number: 0606 • ACR Convergence 2024
Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events
Background/Purpose: Individuals with psoriasis or psoriatic arthritis (PsO/PsA) have an elevated risk ofmajor adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardialinfarction (MI),…Abstract Number: 0880 • ACR Convergence 2024
Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis
Background/Purpose: Alternative pre-mRNA splicing of Vascular Endothelial Growth Factor-A (VEGF-A) produces pro-angiogenic (VEGF-Axxxa) or anti-angiogenic (VEGF-Axxxb) isoforms that contribute to angiogenesis in inflammatory arthritis. Isoform…Abstract Number: 0920 • ACR Convergence 2024
TGF-β Activated Kinase 1 Inhibition by Pentagalloyl Glucose Inhibits NLRP3 Inflammasome Formation and Ameliorates MSU-Induced Inflammation
Background/Purpose: Monosodium urate (MSU)-induced inflammation is caused by the deposition of MSU crystals in the joints and periarticular tissues under conditions of hyperuricemia. These deposits…Abstract Number: 1197 • ACR Convergence 2024
Safety and Immunogenicity of an Active Anti-IL-6 Immunotherapy in a Phase 1 Clinical Trial in Knee Osteoarthritis Patients
Background/Purpose: Interleukin-6 (IL-6) is a major inflammatory cytokine involved in pain and potentially in osteoarthritis (OA) disease progression. PPV-06 is an IL-6-derived peptide coupled with…Abstract Number: 1385 • ACR Convergence 2024
A Novel Oral 3D-Printed Delayed- and Extended-Release Tofacitinib (T19) for the Treatment of Rheumatoid Arthritis and Related Inflammatory Diseases
Background/Purpose: Patients with inflammatory diseases, such as rheumatoid arthritis (RA), frequently continue to suffer from morning symptoms despite treatment with conventional therapies 1,2. Routine morning…Abstract Number: 1462 • ACR Convergence 2024
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors
Background/Purpose: Guselkumab, a fully human IL-23p19-subunit inhibitor, has demonstrated significant and durable efficacy and high rates of patient retention in randomized controlled trials of adults…Abstract Number: 1464 • ACR Convergence 2024
Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Background/Purpose: Many drugs are available in PsA and have demonstrated efficacy in randomized controlled trials (RCTs); however, real-world long-term data of drugs are scarce. PsABIOnd…Abstract Number: 2344 • ACR Convergence 2024
Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study
Background/Purpose: Real-world data on long-term use of secukinumab complements clinical trial findings by providing insights from diverse patients in routine clinical settings. SERENA (CAIN457A3403) was…Abstract Number: 2355 • ACR Convergence 2024
Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified with Machine Learning Analytics Using Data from Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials
Background/Purpose: Risankizumab (RZB), an IL-23 p19 inhibitor, is well tolerated and provides long-term efficacy through 100 weeks in adults with PsA, demonstrated by the phase…Abstract Number: 2581 • ACR Convergence 2024
Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
Background/Purpose: Patients with psoriasis often develop psoriatic arthritis (PsA), a chronic systemic inflammatory disease with a severe clinical burden that impairs quality of life. In…Abstract Number: 0074 • ACR Convergence 2024
Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity
Background/Purpose: Psoriatic arthritis (PsA), a chronic progressive inflammatory arthritis, affects peripheral joints and causes patient disability. PsA patients also have skin plaques initiated by activation…Abstract Number: 2582 • ACR Convergence 2024
Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Background/Purpose: Sonelokimab is a novel humanized Nanobody designed to inhibit IL-17A and IL-17F and penetrate clinically relevant sites of inflammation. The 24-week Phase 2 ARGO…Abstract Number: 0278 • ACR Convergence 2024
Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study
Background/Purpose: The GUARD (Genakumab in high Uric Acid-induced Arthritis/goutfor Resolution and Delay study) program was designed to investigate the efficacy and safety of Genakumab, a…Abstract Number: 2585 • ACR Convergence 2024
Guselkumab and IL-17 Inhibitors Improve Patient-perceived Impact of Psoriatic Arthritis Similarly: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Background/Purpose: PsA leads to significant patient-perceived burden of disease. Targeted drugs have demonstrated efficacy in randomised controlled trials including in aspects of patient-reported impact. However,…
- 1
- 2
- 3
- …
- 11
- Next Page »